A pragmatic blueprint for founders navigating partnerships, acquisitions & momentum
Episode 23 examines a billion-dollar psychedelic acquisition as a case study in how biotech deals truly unfold. Deb, Karim, and Vassili explore why lean teams outperform bloated ones, how IND/Phase 1 often becomes the real sweet spot, and how stretched timelines quietly kill cap tables. They map how milestones, burn rate, and credible data influence acquirers — and discuss adjacent areas, like lupus and women’s health, where timing and non-dilutive capital may collide.
This episode helps founders think through exits before they’re forced to.
Topics:
